LUMOXITI

This brand name is authorized in Brazil, Estonia, Lithuania, Poland, United States

Active ingredients

The drug LUMOXITI contains one active pharmaceutical ingredient (API):

1 Moxetumomab pasudotox UNII 2NDX4B6N8F - MOXETUMOMAB PASUDOTOX

Moxetumomab pasudotox is a CD22-directed cytotoxin. Moxetumomab pasudotox binds CD22 on the cell surface of B-cells and is internalized. Moxetumomab pasudotox internalization results in ADP-ribosylation of elongation factor 2, inhibition of protein synthesis, and apoptotic cell death.

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
LUMOXITI Powder for concentrate solution for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC
LUMOXITI Powder for solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01FB02	Moxetumomab pasudotox	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FB CD22 (Clusters of Differentiation 22) inhibitors
Discover more medicines within L01FB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 502321040034305, 502321040034405
Country: EE	Ravimiamet	Identifier(s): 1840801, 1840812
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1092131, 1092132
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100448631
Country: US	FDA, National Drug Code	Identifier(s): 0310-4700, 73380-4700